Adalimumab, known as Humira, is the best selling drug in the modern world and used to fight Rheumatoid arthritis. However, treatment with this drug is difficult due to the high likelihood of non-response and severe side effects. It is possible to optimize the treatment with therapeutic drug monitoring (TDM), where the dosage of Adalimumab is tailored to the patient based on their drug levels, making treatments more effective and cost-efficient. Methods that are currently available however have long measurement times and high costs, making it very difficult for TDM to become a staple in medical diagnostics and for patients to get the treatment they deserve.
We will develop a point-of-care biosensor that is able to rapidly determine the drug concentration with high precision, making more effective treatments of patients possible.